Another study reported that a microRNA-based strategy was conducive to improving mouse BM-MSC immunotherapy through the FAS/FASL pathway in graft-versus-host disease, inflammatory bowel disease and other immune and inflammatory diseases [39]. The gene discussed is FAS; the disease is graft versus host disease.